
    
The genomic variant c.1799T>G p.Val600Gly rs113488022 is located in the BRAF gene, which encodes a protein that is a member of the RAF kinase family within the RAS/RAF/MEK/ERK signaling pathway. This pathway is involved in regulating cell division, differentiation, and secretion. The BRAF protein plays a central role in this pathway by acting as a kinase that phosphorylates and activates the MEK protein, which in turn activates ERK, leading to the transcription of genes involved in cell proliferation and survival.The c.1799T>G p.Val600Gly variant results in the substitution of valine with glycine at position 600 in the BRAF protein. This position is critical for the kinase activity of BRAF, and mutations at this site can lead to constitutive activation of the BRAF kinase, independent of upstream signals. The variant has been associated with various cancers, including colorectal cancer (CRC), where it has been shown to mediate a distinctive epigenetic mechanism involving the phosphorylation of MAFG and subsequent recruitment of DNA methyltransferase DNMT3B, leading to hypermethylation of CpG islands and an aging-like epigenetic pattern in the genome [2].In CRC, BRAF mutations can be classified into three major categories based on their biological effects. Class I mutations, which include the V600E mutation, result in the formation of an active monomer with kinase activity that is insensitive to upstream signals and downstream negative feedback. This variant is associated with specific clinical features and a poor prognosis in CRC patients, with a higher frequency of metastasis in the peritoneum and distant lymph nodes, and a significant association with right-sided colon tumors, poorer differentiation, mucinous histology, and larger primary tumors [4].The presence of the BRAF V600E mutation has been linked to a distinct distribution of patients according to the frequency of the mutated allele, with a wide range of values observed for the normalized proportion of mutated BRAF alleles [1]. Furthermore, CRC patients with BRAF V600E mutations exhibit distinct prognostic features and differential gene expression patterns, which can classify them into two unique subtypes, BM1 and BM2, with BM1 characterized by poorer prognosis [2].ClinVar submissions for the c.1799T>G p.Val600Gly rs113488022 variant in the BRAF gene indicate a predominance of pathogenic classifications, with a total of 30 pathogenic submissions, 2 somatic with strong clinical significance, 1 oncogenic, and 1 with uncertain significance. This suggests that the variant is predominantly associated with disease, particularly in the context of cancer, where it has been implicated in the pathogenesis and progression of malignancies through its constitutive kinase activity and downstream effects on cell proliferation and survival.

ゲノム変異 c.1799T>G p.Val600Gly rs113488022 は、RAS/RAF/MEK/ERK シグナル伝達経路内の RAF キナーゼファミリーの一員であるタンパク質をコードする BRAF 遺伝子に位置しています。この経路は、細胞分裂、分化、分泌の調節に関与しています。BRAF タンパク質は、この経路において中心的な役割を果たし、キナーゼとして MEK タンパク質をリン酸化して活性化し、次に ERK を活性化させ、細胞増殖と生存に関与する遺伝子の転写を引き起こします。c.1799T>G p.Val600Gly 変異は、BRAF タンパク質の 600 番目の位置でバリンがグリシンに置換される結果をもたらします。この位置は BRAF のキナーゼ活性にとって重要であり、この部位での変異は、上流のシグナルに依存しない BRAF キナーゼの持続的な活性化を引き起こす可能性があります。この変異は、大腸がん（CRC）を含むさまざまな癌と関連しており、MAFG のリン酸化とその後の DNA メチルトランスフェラーゼ DNMT3B のリクルートメントを伴う独特のエピジェネティックなメカニズムを媒介し、CpG アイランドの過剰メチル化とゲノム内の老化様エピジェネティックパターンを引き起こすことが示されています [2]。

CRC において、BRAF 変異はその生物学的効果に基づいて 3 つの主要なカテゴリーに分類されます。クラス I 変異（V600E 変異を含む）は、上流のシグナルや下流の負のフィードバックに対して感受性のないキナーゼ活性を持つ活性型モノマーの形成を引き起こします。この変異は、特定の臨床的特徴および CRC 患者における予後不良と関連しており、腹膜および遠隔リンパ節への転移の頻度が高く、右側結腸腫瘍、分化の低下、粘液性組織学、およびより大きな原発腫瘍との有意な関連が見られます [4]。BRAF V600E 変異の存在は、変異アレル頻度に基づく患者の分布に独特のパターンをもたらし、変異 BRAF アレルの正規化された割合において広範な値が観察されています [1]。さらに、BRAF V600E 変異を有する CRC 患者は、独特の予後的特徴および差異のある遺伝子発現パターンを示し、BM1 および BM2 の 2 つのユニークなサブタイプに分類される可能性があります。BM1 は予後不良であることが特徴です [2]。

ClinVar における BRAF 遺伝子の c.1799T>G p.Val600Gly rs113488022 変異に関する提出データは、病原性分類が優勢であることを示しており、合計 30 件の病原性提出、2 件の強い臨床的意義を持つ体細胞変異、1 件の発がん性、1 件の不明な意義が報告されています。これは、この変異が主に疾患、特に癌の文脈で関連しており、その持続的なキナーゼ活性と細胞増殖および生存に対する下流効果を通じて悪性腫瘍の病因および進行に関与していることを示唆しています。
    
## References
- [1] Blazekovic I et al. (2024). "Association of BRAF V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer." Biomedicines, 12(3) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38540091/)
- [2] Gu R et al. (2024). "A comprehensive overview of the molecular features and therapeutic targets in BRAF(V600E)-mutant colorectal cancer." Clinical and translational medicine, 14(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39073010/)
- [3] Etemadzadeh A et al. (2024). "An Optimized CRISPR/Cas12a Assay to Facilitate the BRAF V600E Mutation Detection." Journal of clinical laboratory analysis, 38(21) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39445676/)
- [4] Deng W et al. (2024). "CXCL16 promotes tumor metastasis by regulating angiogenesis in the tumor micro-environment of BRAF V600E mutant colorectal cancer." Translational oncology, 41() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38232513/)
- [5] Chen F et al. (2024). "Digital Papillary Adenocarcinoma: The Detection of Low-Risk Human Papillomaviruses and the BRAF p.V600E Mutation in a Subset of Cases." Dermatopathology (Basel, Switzerland), 11(3) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39051320/)
- [6] Srisongkram T et al. (2024). "Insights into the structure-activity relationship of pyrimidine-sulfonamide analogues for targeting BRAF V600E protein." Biophysical chemistry, 307() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38241826/)
- [7] Iijima K et al. (2024). "Transcriptional features of low-grade neuroepithelial tumors with the BRAF V600E mutation associated with epileptogenicity." Genes to cells : devoted to molecular & cellular mechanisms, 29(3) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38269481/)
- [8] Kim C et al. (2024). "Differentiating BRAF V600E- and RAS-like alterations in encapsulated follicular patterned tumors through histologic features: a validation study." Virchows Archiv : an international journal of pathology, 484(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38366204/)
- [9] Zhang CX et al. (2024). "BRAF V600E mutation mediates invasive and growth features in ameloblastoma." Oral diseases, 30(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38424736/)
- [10] Martins-de-Barros AV et al. (2024). "BRAF p.V600E Mutational Status Does Not Correlate with Biological Behavior in Conventional Ameloblastomas: A Disease-Free Survival Analysis." Head and neck pathology, 18(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38504068/)
- [11] George GV et al. (2024). "BRAF V600E-Mutant Acute Myeloid Leukemia: A Case Series and Literature Review of a Rare Entity." Genes, 15(11) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39596583/)
- [12] Huang J et al. (2024). "Genetic alterations and allele frequency of BRAF V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study." Clinical and experimental medicine, 24(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38607456/)
- [13] Al Ghafri A et al. (2024). "Analysis of Immunohistochemical Expression of BRAF (V600E) Mutation in Serrated Colorectal Polyps: A Study from Tertiary Hospital in Oman." Asian Pacific journal of cancer prevention : APJCP, 25(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39068592/)
- [14] Behnagh AK et al. (2024). "An Overview on Prevalence and Detection Approaches of BRAF V600E Mutation in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta-Analysis." Iranian journal of public health, 53(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39086414/)
- [15] Ozeki H et al. (2024). "Mucin phenotype and genetic alterations in non-V600E BRAF-mutated colorectal cancer." Human pathology, 145() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38423222/)

    
## ClinVar Submissions
- **[RCV000798913](https://www.ncbi.nlm.nih.gov/clinvar/RCV000798913/)**: RASopathy
- **[RCV000067669](https://www.ncbi.nlm.nih.gov/clinvar/RCV000067669/)**: Melanoma
- **[RCV000080903](https://www.ncbi.nlm.nih.gov/clinvar/RCV000080903/)**: not provided
- **[RCV000443448](https://www.ncbi.nlm.nih.gov/clinvar/RCV000443448/)**: Neoplasm
- **[RCV001030023](https://www.ncbi.nlm.nih.gov/clinvar/RCV001030023/)**: Colorectal cancer
- **[RCV001847607](https://www.ncbi.nlm.nih.gov/clinvar/RCV001847607/)**: See cases
- **[RCV003458334](https://www.ncbi.nlm.nih.gov/clinvar/RCV003458334/)**: Vascular malformation
- **[RCV000014992](https://www.ncbi.nlm.nih.gov/clinvar/RCV000014992/)**: Carcinoma of colon
- **[RCV000014993](https://www.ncbi.nlm.nih.gov/clinvar/RCV000014993/)**: Papillary thyroid carcinoma
- **[RCV000014994](https://www.ncbi.nlm.nih.gov/clinvar/RCV000014994/)**: Astrocytoma, low-grade, somatic
- **[RCV000022677](https://www.ncbi.nlm.nih.gov/clinvar/RCV000022677/)**: Nongerminomatous germ cell tumor
- **[RCV000037936](https://www.ncbi.nlm.nih.gov/clinvar/RCV000037936/)**: Non-small cell lung carcinoma
- **[RCV000432628](https://www.ncbi.nlm.nih.gov/clinvar/RCV000432628/)**: Ovarian neoplasm
- **[RCV000433305](https://www.ncbi.nlm.nih.gov/clinvar/RCV000433305/)**: Lung carcinoma
- **[RCV000433794](https://www.ncbi.nlm.nih.gov/clinvar/RCV000433794/)**: Melanoma

    